GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cryosite Ltd (ASX:CTE) » Definitions » Debt-to-Asset

Cryosite (ASX:CTE) Debt-to-Asset : 0.11 (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Cryosite Debt-to-Asset?

Cryosite's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.17 Mil. Cryosite's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$2.36 Mil. Cryosite's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was A$22.17 Mil. Cryosite's debt to asset for the quarter that ended in Dec. 2023 was 0.11.


Cryosite Debt-to-Asset Historical Data

The historical data trend for Cryosite's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryosite Debt-to-Asset Chart

Cryosite Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.05 0.05 0.04 0.12

Cryosite Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.04 0.12 0.11

Competitive Comparison of Cryosite's Debt-to-Asset

For the Diagnostics & Research subindustry, Cryosite's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryosite's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cryosite's Debt-to-Asset falls into.



Cryosite Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cryosite's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Cryosite's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cryosite  (ASX:CTE) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Cryosite Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cryosite's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryosite (ASX:CTE) Business Description

Traded in Other Exchanges
N/A
Address
13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd is engaged in the provision of supply chain logistics, management of pharmaceutical products used in clinical trials. The company's operating segment includes Cord Blood and Tissue Storage and Clinical Trials and Biological Services Logistics. It generates maximum revenue from the Clinical Trials and Biological Services Logistics segment. Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological services.

Cryosite (ASX:CTE) Headlines

No Headlines